Autologous tumor infiltrating lymphocytes (University of Pittsburgh)

自体肿瘤浸润淋巴细胞（University of Pittsburgh）

Report date: 2022/02/23 09:32:02

Base Information

Drug NameAutologous tumor infiltrating lymphocytes (University of Pittsburgh)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionLymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsBiliary Tract NeoplasmsCholangiocarcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pittsburgh

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pittsburgh

Inactive CompaniesN/A

Active IndicationsBiliary Tract NeoplasmsCholangiocarcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A